Ergocalciferol and Tobi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ergocalciferol (ergocalciferol) and Tobi (tobramycin). Common drug interactions include nausea among females and cough among males.

The phase IV clinical study analyzes what interactions people have when they take Ergocalciferol and Tobi. It is created by eHealthMe based on reports of 63 people who take the same drugs from the FDA, and is updated regularly.

What is Ergocalciferol?

Ergocalciferol has active ingredients of ergocalciferol. It is often used in rickets. eHealthMe is studying from 32,652 Ergocalciferol users. Check the latest studies of Ergocalciferol.

What is Tobi?

Tobi has active ingredients of tobramycin. eHealthMe is studying from 10,011 Tobi users. Check the latest studies of Tobi.

On Jul, 20, 2026

63 people who take Ergocalciferol and Tobi together, and have interactions are studied.

Ergocalciferol and Tobi drug interactions.

What are the common drug interactions of Ergocalciferol and Tobi, by gender? *:

female:

Nausea (feeling of having an urge to vomit)
Suicidal ideation
Anxiety
Dehydration (dryness resulting from the removal of water)
Hypoaesthesia (reduced sense of touch or sensation)
Staphylococcal infection (an infection with staphylococcus bacteria)
Vomiting
C-reactive protein increased
Forced expiratory volume decreased (decreased lung expired air volume)
Chest pain

male:

Cough
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Blood alkaline phosphatase increased
Blood glucose increased
Blood sodium decreased
Forced expiratory volume decreased (decreased lung expired air volume)
Obstructive airways disorder (a progressive disease that makes it hard to breathe)
Stenotrophomonas infection
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Pneumonia

What are the common drug interactions of Ergocalciferol and Tobi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Lobar pneumonia (a form of pneumonia that affects a large and continuous area of the lobe of a lung)
Tracheobronchitis (an inflammation or infection, which affects the trachea and bronchi of respiratory tract)

10-19:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Chest pain
Staphylococcal infection (an infection with staphylococcus bacteria)
Blood alkaline phosphatase increased
Blood glucose increased
Blood potassium increased
Blood sodium decreased
Cough
Forced expiratory volume decreased (decreased lung expired air volume)
Globulins increased

20-29:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Cough
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Pyrexia (fever)
Chills (felling of cold)
Chronic sinusitis (long lasting inflammation of the paranasal sinuses)
Decreased appetite
Myalgia (muscle pain)
Osteoarthritis (a joint disease caused by cartilage loss in a joint)
Pain

30-39:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Distal ileal obstruction syndrome (blockage of the intestines by thickened stool and occurs in individuals with cystic fibrosis)

40-49:

Chest discomfort
Cough
Inflammation
Lower respiratory tract infection
Nephrolithiasis (calculi in the kidneys)
Productive cough
Rhonchi (abnormal breath sounds)
Sputum discoloured
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Pyrexia (fever)

50-59:

Pain
Pharyngitis (inflammation of the pharynx, causing a sore throat)
Cough
Drug ineffective

60+:

Abdominal discomfort
Abdominal distension
Atelectasis (partial or complete collapse of the lung)
Back pain
Blood magnesium decreased
Blood sodium decreased
Bone cyst
Bone disorder
Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)
Bone marrow disorder

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 45 people, 71.43%
Asthma: 11 people, 17.46%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 9 people, 14.29%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 7.94%
Fungal Infection: 5 people, 7.94%
Constipation: 5 people, 7.94%
Sinusitis (inflammation of sinus): 4 people, 6.35%
Sinus Disorder (disease of sinus): 4 people, 6.35%
Pain: 4 people, 6.35%
Obsessive-Compulsive Disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;): 4 people, 6.35%

* Approximation only. Some reports may have incomplete information.

Do you take Ergocalciferol and Tobi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously